Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Key Highlights
- ➤ASPEN-HCM launches to evaluate MYQORZO (CYTK) in real-world symptomatic obstructive HCM
- ➤Study plans approximately 400 patients across 13 cardiology practices and HCM centers
- ➤ASPEN-HCM will track safety, effectiveness, healthcare utilization, and economic outcomes
- ➤MYQORZO (CYTK) carries a boxed heart-failure warning requiring echocardiogram monitoring
Expert Statements
Sanatan Shreay, Executive Director, Head of Health Economics and Outcomes Research at Cytokinetics
“We are pleased to announce the start of ASPEN-HCM, marking an important next step in our ongoing commitment to hypertrophic cardiomyopathy research”
Sanatan Shreay, Executive Director, Head of Health Economics and Outcomes Research at Cytokinetics
“The clinical trials we conducted of MYQORZO provided strong evidence supporting its approval. Now, this study will build on that foundation by generating valuable real-world insights that can help inform clinical decision-making and support clinicians in their everyday practices.”
Theodore Abraham, Co-director, UCSF HCM Center of Excellence
“With our deep commitment to driving innovation in cardiology, this important study is designed to provide critical insights about the impact of the latest non-invasive treatment in HCM, the most common inherited heart disease”
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of ASPEN-HCM (Aficamten Study of Patient Experience and Novel Outcomes in Symptomatic Obstructive HCM), a prospective, multicenter, observational real-world study evaluating MYQORZO® (aficamten) in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.
Get started
Create a free account to read the full story.